Detail of "114899-77-3"

Reference

Progress in the acquisition of new marine-derived anticancer compounds: development of ecteinascidin-743 (ET-743)

Progress in the acquisition of new marine-derived anticancer compounds: development of ecteinascidin-743 (ET-743). Jimeno, Jose M.; Faircloth, Glynn; Cameron, Lewis; Meely, Kathleen; Vega, Eduardo; Gomez, Andres; Sousa-Faro, Jose Ma Fernandez; Rinehart, Kenneth (Pharma Mar, S.A. 114899-77-3 is the cas registry number. This chemical is also mentioned in this article., Research and Development, Madrid 28760, Spain). Drugs of the Future, 21(11), 1155-1165 (English) 1996 Prous. CODEN: DRFUD4. ISSN: 0377-8282. DOCUMENT TYPE: Journal; General Review CA Section: 1 (Pharmacology) Section cross-reference(s): 63 A review, with 65 refs., of the progress in the acquisition of new marine-derived anticancer compds. and development of ecteinascidin-743 (ET-743). .

A phase II and pharmacokinetic study of ecteinascidin 743 in patients with gastrointestinal stromal tumors

A phase II and pharmacokinetic study of ecteinascidin 743 in patients with gastrointestinal stromal tumors. Ryan, David P.; Puchalski, Thomas; Supko, Jeffrey G.; Harmon, David; Maki, Robert; Garcia-Carbonero, Rocio; Kuhlman, Caroline; Winkelman, Jennifer; Merriam, Priscilla; Quigley, Travis; Jimeno, Jose; Manola, Judith; Demetri, George D. (Division of Hematology-Oncology, Harvard Medical School, Massachusetts General Hospital, Boston, MA, USA). Oncologist, 7(6), 531-538 (English) 2002 AlphaMed Press. CODEN: OCOLF6. ISSN: 1083-7159. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacology) To assess the efficacy, tolerability, and pharmacokinetics of ecteinascidin 743 (ET-743) in patients with advanced gastrointestinal stromal tumors (GISTs). The study was confined to adult patients with radiog. measurable GISTs. ET-743 was administered as a 24-h continuous i.v. infusion at a dose of 1.5 mg/m2 repeated every 3 wk. Pharmacokinetic blood sampling was performed during the first cycle of therapy. Tumors were restaged after every second cycle of therapy. A total of 20 patients was enrolled in the study, 19 of whom were treated with 47 cycles of ET-743 (median 2, range 1 - 10). Severe toxicities were limited to reversible grade 3 transaminitis in 10 patients and grade 3 fatigue in one patient.Several substances like 114899-77-3 may be metioned in this study. There were no objective responses, and disease stabilization occurred in two patients lasting for periods of 4 and 10 mo. The 1-yr survival rate was 71.1%. Mean ± std. deviation values of the max. plasma concn. and total plasma clearance were 1.1 ± 0.4 ng/mL and 44 ± 16 l/h/m2, resp., for 19 of the 20 patients. This study is the first report of a prospective phase II trial to evaluate a cytotoxic agent in patients with GISTs. This study underscores the primary resistance of GISTS to chemotherapy and stands in stark contrast to the encouraging results recently achieved with STI571. The lack of response may be assocd. with a therapeutically ineffective exposure to the drug based upon the lower incidence of severe toxicities and greater clearance than described in phase I and II trials of ET-743. .